CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 305 enrolled
Drug / intervention
Pioglitazone and Metformin +1 moredrug
Likely dose
Pioglitazone and Metformin 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00770653
NCT00770653Phase 3Completed
CompareCT.gov

Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia

Takeda·interventional·Posted Oct 10, 2008·Updated Oct 6, 2010

In Brief

A Phase 3 clinical trial evaluating Pioglitazone and Metformin and Glimepiride and Metformin for Diabetes Mellitus and Dyslipidemias. Completed, enrolled 305 participants across 64 sites.

Detailed Summary

The purpose of this study is to compare pioglitazone and metformin combination therapy, twice daily (BID), to glimepiride and metformin combination therapy for treating diabetic subjects with dyslipidemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Dyslipidemias
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 10, 2008
Enrollment StartApr 1, 2007
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.7 years ago

Interventions

Pioglitazone and Metformindrug

Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.

Glimepiride and Metformindrug

Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.